Global Expert Meeting“Race Against Resistance - What Will Happen When Drug
Resistance Spreads?”
Overview
Antimicrobial Resistance (AMR) is causing widespread disruption, with approximately 1.27 million estimated annual
deaths directly linked to AMR, as a British medical journal reported in 2022. AMR has been called a “silent pandemic”
and “The next threat after COVID-19.” The lack of progress in developing new antimicrobials has revealed thenecessity of international cooperation and the importance of pursuing a One Health approach among G7 members
and the global community. It should be noted that countries acting alone cannot fully implement infectious disease
control and that each country’s interests are adjacent to those of the rest of the world. Looking to the UN HighLevel Meeting in 2024, discussions will center on determining the direction and specific measures required,involving stakeholders from government, industry, academia, and civil society. The focus will be on identifying theantibiotic research and development innovation engine. Additionally, assessments of Japan’s leadership within theG7 and the unveiling of forthcoming AMR response plans will be presented.
 Date & Time: Tuesday, April 23, 2024, from 18:00 to 20:00 JST
 Venue: Global Business Hub Tokyo (100-0004, 1 Chome-9-2 Otemachi, Chiyoda City, Tokyo)
In-person attendance only; no online participation is available Language: Japanese and English, with simultaneous interpretation
 Program (titles omitted; in no particular order):18:00 - 18:10
Opening Remarks
Yasuhisa Shiozaki (Member of the Global Leaders Group on Antimicrobial Resistance/ Former
Minister of Health, Labour and Welfare, Japan)
Drew Ferguson (The United States House of Representative)
18:10 - 18:20

Explanatory Introduction
Ryoji Noritake (CEO, Board Member, Health and Global Policy Institute (HGPI))
Yui Kohno (Manager, Health and Global Policy Institute (HGPI))

18:20 - 19:50

Discussion “Race Against Resistance - What Will Happen When Drug Resistance Spreads?”(All speakers and attendees at the venue)
Designated Remarks:
Norio Ohmagari (Director, AMR Clinical Reference Center, National Center for Global Health andMedicine (NCGM))
Keiji Okinaka (Chief, Division of Infectious Diseases (ID) and Infection Control and Prevention
section, National Cancer Center Hospital East (NCCHE) / Staff, Division of Hematopoietic Stem
Cell Transplantation (HSCT), National Cancer Center Hospital (NCCH))
Jun Sugihara (Principal Deputy Director / Director, Office of Ending AIDS Epidemic and Director,
Office of Tuberculosis Elimination, Division of Infectious Disease Prevention and Control,
Department of Infectious Disease Prevention and Control, Public Health Bureau, Ministry of
Health, Labour and Welfare)
Takuko Sawada (Director and Vice Chairperson of the Board, Shionogi & Co., Ltd)Henry Skinner (CEO, AMR Action Fund）

19:50 - 20:00

Closing

Health and Global Policy Institute (HGPI)Grand Cube 3F, Otemachi Financial City, Global Business Hub Tokyo 1-9-2
Otemachi, Chiyoda-ku, Tokyo 100-0004 JAPANTEL: +81-3-4243-7156 FAX: +81-3-4243-7378 E-mail: info@hgpi.org

Speakers Bio (titles omitted; in no particular order)
Norio Ohmagari (Director, Disease Control and Prevention Center (DCC) of National Center for Global Health andMedicine (NCGM) / Director, AMR Clinical Reference Center / Director WHO Collaborating Center for Prevention,
Preparedness and Response to Emerging Infectious Diseases)
Dr. Ohmagari has completed his clinical fellowship in Infectious Diseases at Universityof Texas-Houston. After serving as chief of the Division of Infectious Diseases at the
Shizuoka Cancer Center, in 2011 Dr. Ohmagari moved to National Center for Global
Health and Medicine (NCGM) which is one of six national medical centers in Japan
with infectious diseases as main objective. At NCGM, Dr. Ohmagari has been acting as
Director of the Disease Control and Prevention Center since 2012. In April 2017, hestarted a dual appointment as the Director of the AMR Clinical Reference Center andDirector for the WHO Collaborating Centre for Prevention, Preparedness andResponse to Emerging Infectious Diseases. From November 2023, he became the
Deputy Director for Infection and Crisis Management and from April 2024 holds a dual
appointment at as Deputy Director for Disaster and First Aid.
Keiji Okinaka (Chief, Division of Infectious Diseases (ID) and Infection Control and Prevention section, National
Cancer Center Hospital East (NCCHE) / Staff, Division of Hematopoietic Stem Cell Transplantation (HSCT), National
Cancer Center Hospital (NCCH))
Keiji Okinaka graduated from Hamamatsu University School of Medicine in 2000
before becoming a senior resident in the Division of Infectious Diseases at Shizuoka
Cancer Center Hospital between 2008 and 2011. He was also a senior resident in the
Department of Hematopoietic Stem Cell Transplantation at the National Cancer
Center Hospital in 2011. At the same hospital, between 2011 and 2015, he was a staff
member in both the Division of General Internal Medicine (GIM-ID) and Department
of Hematopoietic Stem Cell Transplantation (HSCT). From 2015 to 2021 he acted as astaff member in the Division of GIM-ID and a Chief of the Infection Control andPrevention section at the National Cancer Center Hospital East, and since 2022 he has
been also be Chief of the Division of Infectious Disease.
Takuko Sawada (Director and Vice Chairperson of the Board, Shionogi & Co., Ltd.)
Following her graduation from Kyoto University, Ms. Takuko Sawada joined Shionogi& Co., Ltd. In 1977. Since then, she has served for over 30 years, leading a number ofpharmaceutical development projects and corporate strategy planning. Ms. Sawada
successively held various posts in the company including the senior vice president of
Global Pharmaceutical Development Division, the senior vice president of Corporate
Strategy Division and Corporate Planning Department, and board director. She hasserved in her current position since 2022

Health and Global Policy Institute (HGPI)Grand Cube 3F, Otemachi Financial City, Global Business Hub Tokyo 1-9-2
Otemachi, Chiyoda-ku, Tokyo 100-0004 JAPANTEL: +81-3-4243-7156 FAX: +81-3-4243-7378 E-mail: info@hgpi.org

Yasuhisa Shiozaki (Member of the Global Leaders Group on Antimicrobial Resistance/ Former Minister of Health,Labour and Welfare, Japan)
A 1975 graduate of the University of Tokyo, he first joined The Bank of Japan andcompleted the MPA at the John F. Kennedy School of Government, at Harvard
University (1982). First elected to the House of Representatives in 1993, he then ran
for the House of Councillors in 1995, and was re-elected to the House ofRepresentatives in 2000, where he served eight terms. After having served as Chief
Cabinet Secretary, Minister of State for the Abduction Issue and Senior Vice-Ministerfor Foreign Affairs, he was appointed as Minister of Health, Labour and Welfare in2014 and held this position until August 2017.

Henry Skinner (CEO, AMR Action Fund)
Dr. Henry Skinner is the Chief Executive Officer of the AMR Action Fund, with nearly$1 billion USD under management to invest in companies worldwide that aredeveloping antimicrobials for priority pathogens and advocate for market reforms tochange how society values these lifesaving drugs. Prior to joining the Fund, Dr. Skinnerheld leadership positions across the pharmaceutical and venture capital sectors,
including serving as Senior Vice President, Venture, at Tekla Capital Management andas Deputy Head and Managing Director of the Novartis Venture Fund. In addition, he
was the CEO of SelectX Pharmaceuticals, which focused on developing small-molecule
antimicrobials, and NeoGenesis Pharmaceuticals, which developed a platform for
identifying and optimizing drug candidates. He was a postdoctoral fellow at Baylor
College of Medicine in the department of Human and Molecular Genetics, and heearned a PhD in Microbiology and an MS in Biochemistry from the University of Illinois.
Jun Sugihara (Principal Deputy Director / Director, Office of Ending AIDS Epidemic and Director, Office ofTuberculosis Elimination, Division of Infectious Disease Prevention and Control, Department of Infectious Disease
Prevention and Control, Public Health Bureau, Ministry of Health, Labour and Welfare)
Dr. Jun Sugihara is a medical officer at the Ministry of Health, Labour and Welfare(MHLW), Japan. Dr. Sugihara currently serves as the Principal Deputy Director of
Infectious Disease Prevention and Control Division and co-assigned as the Director of
the Office of Ending AIDS Epidemic/Office of Tuberculosis Elimination. He also serves
as the Deputy Chief of the Strategic Planning Task Force within MHLW’s COVID-19
Response Headquarters. Prior to his current position, he worked as a Global Health
Security Coordinator and a technical lead for the International Health Regulations
National Focal Point of Japan at MHLW from 2018 to 2021. Dr. Sugihara was deployed
to the U.S. Centers for Disease Control and Prevention and the Office of the Assistant
Secretary for Preparedness and Response in the U.S. Department of Health andHuman Services as a liaison to coordinate bilateral health security issues from 2016 to2018. Before joining MHLW, he worked as a clinician specialized in infectious diseaseat the National Center for Global Health and Medicine in Japan and a consultant of
the World Health Organization Western Pacific Regional Office. Dr. Sugihara received
his medical degree from Yokohama City University, Master of Public Health from Johns
Hopkins Bloomberg School of Public Health and the Postgraduate Diploma in Tropical
Medicine and Hygiene from London School of Hygiene and Tropical Medicine. He is an
Infectious Disease Emergency Management Specialist certified by MHLW.

Health and Global Policy Institute (HGPI)Grand Cube 3F, Otemachi Financial City, Global Business Hub Tokyo 1-9-2
Otemachi, Chiyoda-ku, Tokyo 100-0004 JAPANTEL: +81-3-4243-7156 FAX: +81-3-4243-7378 E-mail: info@hgpi.org

Drew Ferguson (The United States House of Representative)
Congressman Drew Ferguson is a Republican member of the U.S. House ofRepresentatives. His tenure representing the State of Georgia’s 3rd Congressional
District began on 3 January 2017. He is a longtime champion of efforts to battle drugresistant infections, and in December 2020 introduced the bipartisan, bicameral
Pioneering Antimicrobial Subscription To End Upsurging Resistance (PASTEUR) Act,
which encourages innovative drug development targeting the most threatening
infections, improves the appropriate use of antibiotics, and ensures domestic
availability of antibiotics when needed. He reintroduced the bill, which establishes afully delinked subscription model with contracts that could be valued between $750
million and $3 billion USD, in April 2023. Rep. Ferguson sits on the House Committee
on Budget and the Committee on Ways and Means. Previously, Rep. Ferguson spenteight years as mayor of West Point, Georgia. He graduated from the University ofGeorgia and received a degree in dental medicine from the Medical College of Georgia.
Ryoji Noritake (CEO, Board Member, Health and Global Policy Institute)
Mr. Ryoji Noritake is the CEO, and Board Member of Health and Global Policy Institute(HGPI), a Tokyo-based independent and non-profit health policy think tankestablished in 2004. He also served as Asia-Pacific Lead for Project HOPE, a US-based
medical humanitarian aid organization. Through HOPE and HGPI, he has led healthsystem strengthening projects in the Asia-Pacific region and engaged in the US Navy’s
medical humanitarian projects. His focus is a multi-sectoral approach to health issues
such as public-private partnerships and civil-military coordination. He was a memberof the Tokyo Metropolitan Government’s Policy Discussion Roundtable for Super
Ageing Society (2018) and served as a Visiting Scholar at the National Graduate
Institute for Policy Studies (2016-2020). He is currently serving as a member of World
Dementia Council (WDC), the Salzburg Global Seminar’s Advisory Council, Advisory
Board Member of Elsevier Atlas, and the Dementia Innovation Alliance hosted by the
Ministry of Economy, Trade and Industry (METI), Japan. He was awarded the 32th
Takemi Incentive Award in 2022. He is a graduate of Keio University’s Faculty of Policy
Management and holds a MSc in Medical Anthropology from the University of
Amsterdam, the Netherlands.
Yui Kohno (Manager, Health and Global Policy Institute)
Ms. Yui Kohno is a graduate of the University of Sydney School of Public Health’s
Faculty of Medicine and Health in Australia. After obtaining a Master of Health Policy
degree from the University of Sydney, Ms. Kohno joined Health and Global Policy
Institute. There, she is responsible for research and analysis of national and global
policy challenges within and beyond the fields of Antimicrobial Resistance (AMR) andvaccination. Her activities include planning and coordinating conferences for better
policy dialogue and discussion and engaging in public relations, outreach, andadvocacy activities.

Health and Global Policy Institute (HGPI)Grand Cube 3F, Otemachi Financial City, Global Business Hub Tokyo 1-9-2
Otemachi, Chiyoda-ku, Tokyo 100-0004 JAPANTEL: +81-3-4243-7156 FAX: +81-3-4243-7378 E-mail: info@hgpi.org

About Health and Global Policy Institute (HGPI)
Health and Global Policy Institute (HGPI) is a non-profit, independent, non-partisan health policy think tankestablished in 2004. As a neutral think-tank, HGPI involves stakeholders from wide-ranging fields of expertise toprovide policy options to the public to create citizen-focused healthcare policies successfully. Looking to the future,
HGPI produces novel ideas and values from a comprehensive perspective. It aims to realize a healthy and fair society
while holding fast to its independence to avoid being bound to the specific interests of political parties and otherorganizations. HGPI intends for its policy options to be effective in Japan and the broader world. In this vein, theinstitute will continue to actively create policies for resolving global health challenges. HGPI’s activities have received
international recognition. It was ranked second in the “Domestic Health Policy Think Tanks” category and third inthe “Global Health Policy Think Tanks” category in the Global Go To Think Tank Index Report presented by the
University of Pennsylvania (as of January 2021, the most recent report).
About AMR Alliance JapanAMR Alliance Japan is an independent platform for the promotion of multisector discussion on AMR
countermeasures. Since its establishment in November 2018, AMR Alliance Japan has worked with Alliancemembers and partner organizations to deepen policy debate around AMR. Current Members (as of April, 2024) are
bioMérieux Japan Ltd., GlaxoSmithKline K.K., Himeji City, Japan Medical Association, Japan Pharmaceutical
Association, Japan Pharmaceutical Manufacturers Association, Japanese Association of Medical Technologists,
Japanese Society for Pediatric Infectious Diseases, Japanese Society of Antimicrobials for Animals, Japanese Societyof Chemotherapy, Japanese Society of Hospital Pharmacists, “Kodomo to lryo” Project, Meiji Seika Pharma Co., Ltd.,MSD K.K., Nippon Becton, Dickinson and Company, Ltd., Pfizer Japan Inc., Shimadzu Diagnostics Corporation,
Shionogi & Co., Ltd., Sumitomo-Pharma Co., Ltd., The Japanese Society for Medical Mycology, The Japanese
Association for Infectious Diseases, The Japanese Society for Clinical Microbiology, The Japanese Society for
Infection Prevention and Control, The Japanese Society of Pharmaceutical Health Care and Sciences, The JapaneseSociety of Therapeutic Drug Monitoring, The Pharmaceutical Society of Japan, Health and Global Policy Institute(HGPI) serves as Secretariat of the Alliance.
Health and Global Policy Institute: Guidelines on Grants and Contributions
As an independent, non-profit, non-partisan private think tank, HGPI complies with the following guidelines relating
to the receipt of grants and contributions.
1. Approval of Mission
The mission of HGPI is to improve the civic mind and individuals’ well-being, and to foster a sustainable healthy
community by shaping ideas and values, reaching out to global needs, and catalyzing society for impact. The
activities of the Institute are supported by organizations and individuals who are in agreement with this mission.
2. Political Neutrality
HGPI is a private, non-profit corporation independent of the government. Moreover, we receive no support fromany political party or other organization whose primary purpose is political activity of any nature.
3. Independence of Project Planning and Implementation
HGPI makes independent decisions on the course and content of its projects after gathering the opinions of a broad
diversity of interested parties. The opinions of benefactors are solicited, but the Institute exercises independentjudgment in determining whether any such opinions are reflected in its activities.
4. Diverse Sources of Funding
In order to secure its independence and neutrality, HGPI will seek to procure the funding necessary for its operationfrom a broad diversity of foundations, corporations, individuals, and other such sources. Moreover, as a general rule,funding for specific divisions and activities of the Institute will also be sought from multiple sources.
5. Exclusion of Promotional Activity
HGPI will not partake in any activity of which the primary objective is to promote or raise the image or awarenessof the products, services or other such like of its benefactors.
6. Written Agreement
Submission of this document will be taken to represent the benefactor’s written agreement with HGPI’s compliancewith the above guidelines.

Health and Global Policy Institute (HGPI)Grand Cube 3F, Otemachi Financial City, Global Business Hub Tokyo 1-9-2
Otemachi, Chiyoda-ku, Tokyo 100-0004 JAPANTEL: +81-3-4243-7156 FAX: +81-3-4243-7378 E-mail: info@hgpi.org